论文部分内容阅读
Objective: The aim of our study was to evaluate the short-term efficacy and the toxic reaction of nedaplatin concurrent with radiotherapy for mid-advanced nasopharyngeal carcinoma and esophageal carcinoma.Methods: Thirty-four patients were confirmed diagnosis with cancer by pathologic results.All patients were given 6MV X-ray for radiotherapy,Dt 66--70 Gy/33-35 f/6-7 w,concurrently administrated nedaplatin(30 mg/m2)once a week(6 times).Results: A total 34 patients were enrolled,of whom 33 patients were available for objective response,1 patient of esophageal cancer quit for allergic reaction.The response rate(RR)of nedaplatin-contained therapy for nasopharyngeal carcinoma and esophageal carcinoma were 90.0% and 76.9%,respectively.The major toxic reaction was bone marrow suppression observed in 25 patients(73.5%), in which grade Ⅲ aleukocytosis was observed in 3 patients(8.8%),grade Ⅲ+Ⅳ thrombocytopenia in 3 patients(8.8%).And 6 patients(17.6%)showed gastrointestinal tract reaction.There were 4 patients with radiation esophagitis in the 13 patients with esophageal carcinoma.Conclusion: Nedaplatin can increase the therapeutic effect of radiation.Its incidence rate of bone marrow suppression is high,but the gastrointestinal tract reaction and renal toxicity is low and mild.